3-oxo-5-alpha-steroid 4-dehydrogenase | |||||||
---|---|---|---|---|---|---|---|
Identifiers | |||||||
EC number | 1.3.99.5 | ||||||
CAS number | 9036-43-5 | ||||||
Databases | |||||||
IntEnz | IntEnz view | ||||||
BRENDA | BRENDA entry | ||||||
ExPASy | NiceZyme view | ||||||
KEGG | KEGG entry | ||||||
MetaCyc | metabolic pathway | ||||||
PRIAM | profile | ||||||
PDB structures | RCSB PDB PDBe PDBsum | ||||||
Gene Ontology | AmiGO / EGO | ||||||
|
steroid-5-alpha-reductase, alpha polypeptide 1 | |
---|---|
Identifiers | |
Symbol | SRD5A1 |
Entrez | 6715 |
HUGO | 11284 |
OMIM | 184753 |
RefSeq | NM_001047 |
UniProt | P18405 |
Other data | |
EC number | 1.3.99.5 |
Locus | Chr. 5 p15 |
steroid-5-alpha-reductase, alpha polypeptide 2 | |
---|---|
Identifiers | |
Symbol | SRD5A2 |
Entrez | 6716 |
HUGO | 11285 |
OMIM | 607306 |
RefSeq | NM_000348 |
UniProt | P31213 |
Other data | |
EC number | 1.3.99.5 |
Locus | Chr. 2 p23 |
5α-reductases, also known as 3-oxo-5α-steroid 4-dehydrogenases, are enzymes involved in steroid metabolism. They participate in 3 metabolic pathways: bile acid biosynthesis, androgen and estrogen metabolism, and prostate cancer.
5α-reductases catalyze the following chemical reaction:
Thus, the two substrates of these enzymes are an 3-oxo-5α-steroid and acceptor, whereas its two products are 3-oxo-Delta4-steroid and a reduced acceptor.
Contents |
5α-reductases convert testosterone, the male sex hormone, into the more potent dihydrotestosterone:
Note the major difference — the Δ4,5 double-bond on the A (leftmost) ring. (The other differences between the diagrams are unrelated to chemical structure.)
These enzymes also participate in the creation of such neurosteroids as allopregnanolone and THDOC.
There are two isoenzymes, steroid 5α-reductase 1 and 2 (SRD5A1 and SRD5A2).[1][2]
The second isoenzyme is deficient in 5α-reductase deficiency, which leads to a form of intersexualism.
The enzyme is produced only in numerous tissues in both males and females especially in tissues of the reproductive tract, testis and ovary,[3] namely the skin, seminal vesicles, prostate and epididymis.
Inhibition of 5α-reductase results in decreased production of DHT, increased levels of testosterone, and, perhaps, increased levels of estradiol. Gynecomastia is a possible side-effect of 5α-reductase inhibition.
5α-reductase inhibitor drugs are used in benign prostatic hyperplasia, prostate cancer, male pattern baldness, and hormone replacement therapy (male to female) for transgendered women. Both isoforms are also produced in the brain, where they serve to create the neurosteroid allopregnanolone (5AR type I) and convert T to DHT(5AR type II)(1). Finasteride inhibits the function of only one of the isoenzymes (type 2), whereas dutasteride inhibits both forms. Saw palmetto extract also inhibits both forms.
This enzyme belongs to the family of oxidoreductases, to be specific, those acting on the CH-CH group of donor with other acceptors. The systematic name of this enzyme class is 3-oxo-5α-steroid:acceptor Delta4-oxidoreductase. Other names in common use include steroid
|
|